![](\"https:\/\/mms.businesswire.com\/media\/20260625665011\/en\/2838570\/5\/nomic-oasis_PR.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260625665011\/en\/2838569\/5\/logo_-_dark_type%403x.jpg\"){kind=logo}
<\/a><\/a>\nThe OASIS Consortium is designed to support more predictive, efficient, and human-relevant approaches to compound safety assessment, consistent with the growing adoption of New Approach Methodologies (NAMs) across the pharmaceutical and regulatory landscape. As part of the study, Nomic\u2019s Omni 1000 platform will be used to profile more than 3,000 HepaRG cell supernatant samples treated with 168 compounds, generating a proteomic training dataset that can support the development of predictive toxicity models while providing biological insight into the pathways and mechanisms underlying adverse effects.<\/p>
\nProteins are the functional layer of biology. Comprehensive proteomics profiling may capture pathway-level changes associated with cellular stress, toxic response, cell death, inflammation, and mechanisms of injury. The resulting protein-level dataset is expected to provide both the training data needed to build more accurate predictive models and the mechanistic context required to understand why those models make specific predictions. As AI and computational approaches become increasingly important in safety assessment, proteomic data can help bridge prediction and biological interpretation, improving confidence in human-relevant pre-clinical models.<\/p>
\nNomic will conduct proteome-wide profiling with Nomic Omni 1000 to discover safety or toxicity relevant protein signatures, with the potential to translate those findings into a smaller, fit-for-purpose panel using Nomic\u2019s adaptable Flex offering. \u201cHuman-relevant datasets are essential to advancing more predictive safety assessment,\u201d said Milad Dagher, CEO of Nomic. \u201cThis study is designed to generate large-scale proteomic datasets across diverse compound exposures, creating resources that can support toxicity prediction efforts while providing pathway-level biological context alongside computational approaches.\u201d<\/p>
\nNomic\u2019s platform reports protein measurements in absolute concentration units (pg\/mL), enabling comparable data across experiments, compounds, doses, and model systems. This interoperability is particularly important for safety science, where shared, analysis-ready datasets can help accelerate the development of more broadly useful predictive models.<\/p>
\n\u201cThe goal of OASIS is to generate high-quality, shared scientific resources that help move safety assessment toward more predictive and human-relevant models,\u201d said Chrissy Crute, Ph.D., Scientific Program Manager at HESI Global. \u201cProteomics can enable researchers to measure pathway-level biological responses to compound exposure. The resulting proteomics datasets will be combined with Cell Painting and transcriptomics to support the development of more predictive NAMs while also helping researchers understand the biological mechanisms that drive toxic responses. This data will support the OASIS\u2019s Consortium\u2019s goal to advancement in vitro tools and multimodal assessments.\u201d<\/p>
\nThe collaboration is expected to generate publishable, publicly available results that can benefit the broader research community and contribute to shared progress in new approach methodologies for drug toxicity and risk assessment.<\/p>
\nLearn more about the Nomic\u2019s proteomics solutions here<\/a>.<\/p> \nLearn more about HESI Global<\/a> and the OASIS Consortium<\/a>.<\/p> \nAbout Nomic Bio\n